Aliases:This biomarker is also known as:
- tyrosine-protein kinase Kit,
- p145 c-kit,
- Piebald trait,
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein,
- proto-oncogene tyrosine-protein kinase Kit,
- Piebald trait protein,
- soluble KIT variant 1,
- mast/stem cell growth factor receptor Kit,
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog,
- proto-oncogene c-Kit,
- CD117 antigen,
SCF-sR, also known as KIT, is the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. Human KIT is a tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KIT is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
KIT is known to be expressed in poorly differentiated breast cancer. (PMID:17867595). KIT is also thought to be a possible prognostic marker and possible molecular target for therapy in patients with BLBC. (PMID: 23319435)
KIT was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
KIT has not been identified previously in serum as a lung cancer biomarker and represents a novel finding in the aptamer proteomic technology study (Ostroff et al, 2010).
SCF-sR, also known as KIT, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
- C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
- c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
- The State of Molecular Biomarkers for the Early Detection of Lung Cancer.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.